Gain Therapeutics (NASDAQ:GANX) Rating Increased to Strong-Buy at Roth Capital

Gain Therapeutics (NASDAQ:GANX) was upgraded by equities research analysts at Roth Capital to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other analysts have also commented on GANX. Oppenheimer reissued an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Wednesday, August 14th. Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday, August 9th. Roth Mkm assumed coverage on Gain Therapeutics in a research note on Friday. They set a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.25.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock opened at $1.79 on Thursday. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $5.33. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $2.09 and its two-hundred day moving average price is $1.69. The stock has a market cap of $47.47 million, a PE ratio of -1.63 and a beta of 0.21.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GANX. Warberg Asset Management LLC acquired a new stake in Gain Therapeutics during the 2nd quarter valued at $66,000. Renaissance Technologies LLC grew its holdings in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares in the last quarter. Geode Capital Management LLC raised its position in Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth about $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.